Stoke Therapeutics, Inc.

NASDAQ:STOK

Biotechnology

Healthcare
$26.69 -1.12%

-$0.34 today

Market cap
$1.75B
Beta
1.19
P/E (TTM)
-11.1
EPS (TTM)
-$2.69
52W Low $11.17High $40.22

Volume 0.76M

Average 0.64M

STOK Interest Expense

Cost of servicing the company's debt during the period.

Stoke Therapeutics, Inc.NASDAQ: STOK

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense grows, but more slowly than its trailing trend

Q1 FY2026 interest expense of $3.4M rose 339600.0% year over year, behind the +340500.0% change in trailing-twelve-month interest expense. Sequentially, it rose 113133.3% from the prior quarter.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +339600.0% toward the trailing-twelve-month pace of +340500.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.4M+113133.3% QoQ
Last fiscal yearDec 2025
$9K— YoY
LTMMar 2026
$3.41M+340500.0% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+339600.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
9K USD
Year-over-year change
—

Interest Expense vs competitors

How STOK compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +340500.0% is the highest of 3, against a peer median of -58.1%.
  • Interest expense amounts to 10.6% of revenue for STOK, versus a peer median of 0.0%.
STOK Competitors
Interest Expense for STOK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$76.07M USD-16.1%+123.4%7.9%
STOKStoke Therapeutics, Inc.LTM Mar 2026$3.41M USD+340500.0%—10.6%
BEAMBeam Therapeutics Inc.LTM Jun 2026$0 USD——0.0%
SLNSilence Therapeutics plcLTM Mar 2026$0 USD——0.0%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$0 USD———
WVEWave Life Sciences Ltd.LTM Mar 2026$0 USD——0.0%
PRQRProQR Therapeutics N.V.LTM Mar 2026€0 EUR-100.0%-44.7%0.0%
Peer median (excluding STOK) —-58.1%+39.3%0.0%

Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue012.41M8.78M36.56M184.42M
Cost of Revenue00000
Gross Profit012.41M8.78M36.56M184.42M
Gross Margin—100.0%100.0%100.0%100.0%
Research & Development54.17M77.84M82.23M89.13M137.92M
Selling, General & Admin31.9M38.92M41.32M48.79M67.09M
Operating Expenses86.07M116.76M123.55M137.93M205.01M
Depreciation & Amortization974K1.55M2.47M2.18M1.77M
EBITDA(84.83M)(99.52M)(102.23M)(86.8M)(5.12M)
EBITDA Margin—-802.3%-1164.4%-237.5%-2.8%
Operating Income(86.07M)(104.36M)(114.77M)(101.37M)(20.59M)
Operating Margin—-841.2%-1307.2%-277.3%-11.2%
Interest Income120K3.12M9.91M12.64M13.77M
Interest Expense00009K
Other Income / Expenses260K3.29M10.07M12.39M13.71M
Income Before Tax(85.81M)(101.07M)(104.7M)(88.98M)(6.89M)
Pre-Tax Margin—-814.7%-1192.5%-243.4%-3.7%
Income Tax Expense00000
Net Income(85.81M)(101.07M)(104.7M)(88.98M)(6.89M)
Net Margin—-814.7%-1192.5%-243.4%-3.7%
EPS (Basic)(2.34)(2.60)(2.38)(1.65)(0.12)
EPS (Diluted)(2.34)(2.60)(2.38)(1.65)(0.12)
Weighted Avg Shares36.74M38.9M43.99M54.01M59.22M
Weighted Avg Shares (Diluted)36.74M38.9M43.99M54.01M59.22M

Stoke Therapeutics, Inc.

NASDAQ:STOK

Intrinsic Alpha fair value

Locked

Current Price

$26.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.